Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.

[1]  R. Motzer,et al.  Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience. , 1992, Seminars in oncology.

[2]  A. Horwich,et al.  The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Fosså,et al.  Original article: BOP/VIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours , 1991 .

[4]  S. Fosså,et al.  BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  N. Geller,et al.  Prognostic factors in metastatic germ cell tumors. , 1990, Progress in clinical and biological research.

[6]  A. V. van Oosterom,et al.  Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Horwich,et al.  Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours. , 1989, European journal of cancer & clinical oncology.

[8]  L. Einhorn,et al.  Ifosfamide in testicular cancer: the Indiana University experience. , 1989, Seminars in oncology.

[9]  E. Newlands,et al.  Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis. , 1989, British Journal of Cancer.

[10]  M. Cullen,et al.  Chemotherapy for poor risk germ cell tumours. An independent evaluation of the POMB/ACE regime. , 1988, British journal of urology.

[11]  W. M. Linehan,et al.  A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  N. Geller,et al.  Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Einhorn,et al.  Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. , 1987, The New England journal of medicine.

[14]  I. Pastan,et al.  Multiple-drug resistance in human cancer. , 1987, The New England journal of medicine.

[15]  N. Geller,et al.  Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Sylvester,et al.  High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Logothetis,et al.  Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients. , 1986, The American journal of medicine.

[18]  G. Bosl,et al.  Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors. , 1985, The American journal of medicine.

[19]  K. Sikora,et al.  PROGNOSTIC FACTORS IN ADVANCED NON-SEMINOMATOUS GERM-CELL TESTICULAR TUMOURS: RESULTS OF A MULTICENTRE STUDY Report from the Medical Research Council Working Party on Testicular Tumours , 1985, The Lancet.

[20]  J H Goldie,et al.  The genetic origin of drug resistance in neoplasms: implications for systemic therapy. , 1984, Cancer research.

[21]  N. Geller,et al.  Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. , 1983, Cancer research.

[22]  J H Goldie,et al.  Rationale for the use of alternating non-cross-resistant chemotherapy. , 1982, Cancer treatment reports.

[23]  L. Einhorn.  Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. , 1981, Cancer research.

[24]  L. Einhorn,et al.  VP‐16–213 salvage therapy for refractory germinal neoplasms , 1980, Cancer.